Global Orphan Drug Market

Global Orphan Drug Market Size, Share, Growth Analysis, By Disease Type(Oncological diseases, metabolic diseases), By Drug Type(Biologics, Non-biologics) - Industry Forecast 2023-2030


Report ID: SQMIG30A2005 | Region: Global | Published Date: February, 2024 | Pages: 211 | Tables: 65 | Figures: 75

Global Orphan Drug Market Insights

Orphan Drug Market size was valued at USD 87.44 billion in 2021 and is poised to grow from USD 174.11 billion in 2022 to USD 359.86 billion by 2030, growing at a CAGR of 9.5% in the forecast period (2023-2030).

Orphan drugs are designed to treat illnesses that are so uncommon that their sponsors are reluctant to develop them under standard marketing guidelines.

According to the World Health Organization (WHO), this condition occurs less frequently than 6.5 to 10 times per 10,000 people.

The journey from a new molecule's discovery to its commercialization often takes ten years, costs several tens of millions of euros, and is fraught with uncertainty (among ten molecules tested, only one may have a therapeutic effect). The money spent on its research cannot be recouped when a medicine is developed to treat a rare condition.

Since the introduction of the Orphan Drug Act in 1983, intended to promote development of treatments for rare diseases, at least 378 orphan drugs have been approved. Kalydeco may be the orphan drug of all orphan drugs.

The U.S. dominated development of orphan drugs, with more than 300 in clinical trials, followed by Europe. Cancer treatment was the indication in more than 30% of orphan drug trials.

There are currently approximately 7000 rare diseases listed on the National Institute of Health’s (NIH) Office of Rare Diseases website, affecting an estimated 25–30 million people within the United States3, most of these rare diseases are genetic and many are neurological. Approximately 250 new rare diseases are described each year4, and with advances in genetics, many more common disorders will be subdivided into genetically distinct “rare” diseases.

US Orphan Drug Market is poised to grow at a sustainable CAGR for the next forecast year.

Market snapshot - 2023-2030

Global Market Size

USD 87.44 billion

Largest Segment

Biologics

Fastest Growth

Non-biologics

Growth Rate

9.5% CAGR

Global Orphan Drug Market, 2021-2028($ Bn)
Country Share for North America Region- 2021 (%)
Global Orphan Drug Market Size By Drug Type , 2021-2028 ($ Bn)
Global Orphan Drug Market Size By Drug Type , 2021-2028 (%)

To get more reports on the above market click here to Buy The Report

Global Orphan Drug Market Segmental Analysis

The Global Orphan Drug Market is segmented based on the Disease Type, Drug Type, and region. Based on the Disease Type, the Global Orphan Drug Market is segmented as Oncological diseases, metabolic diseases, hematologic & immunologic diseases, infectious diseases, neurologic diseases, and other rare diseases and Others.

Based On Drug Type, the Global Orphan Drug Market is segmented as biologics and non-biologics.

Based on Region Orphan Drug Market is categorized into North America, Europe, Asia-Pacific, Latin America, and MEA.

Orphan Drug Market Analysis by Disease Type

Oncological diseases, metabolic diseases, hematologic & immunologic diseases, infectious diseases, neurologic diseases, and other rare diseases, which also include transplantation diseases, gastrointestinal diseases, dermatologic diseases, perinatal & congenital abnormalities, and others, are the disease types that the orphan drugs market is divided into by category. Acute myeloid leukaemia (AML), pancreatic cancer, ovarian cancer, multiple myeloma, renal cell carcinoma, and other cancers are included in the classification of oncological illnesses. Huntington syndrome, Fabry disease, Gaucher disease, hypoparathyroidism, and other are further subtypes of metabolic illnesses. Hematologic and immunologic illnesses are further divided into haemophilia, hereditary angioedema, and other conditions. Duchenne muscular dystrophy (DMD), Alzheimer's disease, Huntington's disease, and other neurologic illnesses are further divided into subcategories.

Due to an increase in the prevalence of oncological illnesses, increased public awareness of cancer, the availability of oncological orphan medications for the treatment of cancer, and a surge in early cancer detection, the oncological disorders segment had the largest shareholder in 2021.

Orphan Drug Market Analysis by Drug Type

The Global Orphan Drug Market has been segmented on the basis of Drug Type as biologics and non-biologics. One of the main causes of the segment's domination in 2019 is the preponderance of product offerings that are categorized as biologics. The U.S. Food and Drug Administration (U.S. FDA) estimates that over 600 medicines and biologic products for rare conditions have been developed and marketed thanks to the organization's Orphan Products Development (OOPD) since 1983. The non-biologics market sector had a smaller market share overall and a lower CAGR than other segments.

Global Orphan Drug Market By Drug Type , 2021(%), 2021 (%)

To get detailed analysis on other segments, Request For Sample Report

Global Orphan Drug Market Regional Insights

In terms of CAGR, North America is expected to grow quickly in the years to come. This is attributed to the increase in patients in this area who are susceptible to rare diseases. The unhealthy lifestyle and stressful lifestyle are the key factors that cause this disease to spread in this area. In order to reduce the number of patients brought on by this disease, government organisations like NGO are investing a significant amount of money in this region.

Also, the European Orphan Drug Market would grow in the coming years, due to the large patient population in the area and the widespread use of complex medicines for uncommon diseases. Due to rising healthcare costs and greater awareness of rare diseases, the market in Asia Pacific is expected to expand at the fastest rate. Latin America, the Middle East, and Africa made up the Rest of the World, which accounted for a smaller share of the worldwide market due to the under-penetration of the market.

Global Orphan Drug Market By Geography, 2021 - 2028, 2023-2030
  • Largest
  • Fastest

To know more about the market opportunities by region and country, click here to
Buy The Complete Report

Global Orphan Drug Market Dynamics

Orphan Drug Market Driver

  • The development of orphan medications under research has been significantly influenced by the development of new technologies.  Due recent advancements in genomics and the wider application of gene sequencing, made it possible in case of rare disease.  furthermore, additional technologies like gene therapy and antisense therapy have made it feasible for us to target certain disorders in ways that were not previously possible.  Combined, technological advancements have made it easier to both diagnose and cure uncommon genetic disorders, which has made them more manageable for pharmaceutical companies.
  • Even though there is a small patient pool, factors including incentives, accelerated development schedules, and high regulatory approval rates make developing drugs for rare diseases cost effective.

Orphan Drug Market Restraint

  • Orphan medications frequently fall short of established health technology assessment criteria, particularly cost-effectiveness, which may affect access, due to high costs and a lack of data.
  • One of the major challenges in these markets is finding qualified patients for clinical trials of orphan drugs. Additionally, a thorough understanding of the biology of the disease is necessary for efficient recruiting in uncommon disorders.

Speak to one of our ABIRAW analyst for your custom requirements before the purchase of this report

Global Orphan Drug Market Competitive Landscape

The Global Orphan Drug Market is relatively fragmented, with a high level of competition. The prominent players operating in the orphan drug market are constantly

Orphan Drug Market Top Player's Company Profiles

  • Vertex Pharmaceuticals
  • Alexion Pharmaceuticals
  • BioMarin Pharmaceutical
  • Shire (now part of Takeda)
  • Sanofi Genzyme
  • Celgene (now part of Bristol Myers Squibb)
  • Genentech (a subsidiary of Roche)
  • Pfizer
  • Novartis
  • Johnson & Johnson
  • AbbVie
  • Amgen
  • Ultragenyx Pharmaceutical
  • CSL Behring
  • Merck & Co.
  • Grifols
  • Sobi (Swedish Orphan Biovitrum)
  • Ipsen
  • Jazz Pharmaceuticals
  • AstraZeneca

Orphan Drug Market Recent Developments

  • In April 2022, according to news, the product's creator Shanghai Henlius Biotech, the FDA has qualified serplulimab, also known as Hansizhuang, as an orphan medication for the treatment of small-cell lung cancer.
  • In March 2022, ABIONYX Pharma reported that the USFDA had granted Bio-HDL CER-001 orphan-drug designation (ODD) for the treatment of lecithin-cholesterol acyltransferase deficiency, also known as LCAT deficiency.

Global Orphan Drug Key Market Trends

  • Since companies employ far lower criteria for showing treatment effectiveness, the expansion of the use of auxiliary or surrogate endpoints within clinical trials for orphan pharmaceuticals has significantly reduced the time and cost needed to undertake R&D. This can accelerate the growth of the Orphan Drug Market. 
  • Patients throughout the world looking for effective and efficient therapy for rare diseases. Newer and more effective product offerings are being introduced as a result of growing R&D initiatives and growing patient advocacy for effective therapy. These developments have resulted in the creation and distribution of multiple blockbuster medications for the treatment of various malignancies, immune disorders, and other rare diseases. 

Global Orphan Drug Market SkyQuest Analysis

SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Co-relates, and Analyses the Data collected utilizing Primary Exploratory Research backed by the robust Secondary Desk research.

According to our Global Orphan Drug Market Analysis, in terms of drug type, the availability of oncological orphan medications for the treatment of cancer, and a surge in early cancer detection, the oncological disorders segment had the largest shareholder in 2021. Combined, technological advancements have made it easier to both diagnose and cure uncommon genetic disorders, which has made them more manageable for pharmaceutical companies.

Report Metric Details
Market size value in 2021 USD 87.44 billion
Market size value in 2030 USD 359.86 billion
Growth Rate 9.5%
Base year 2021
Forecast period 2023-2030
Forecast Unit (Value) USD Billion
Segments covered
  • Disease Type
    • Oncological diseases, metabolic diseases, hematologic & immunologic diseases, infectious diseases, neurologic diseases, Others
  • Drug Type
    • Biologics, Non-biologics
Regions covered North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA)
Companies covered
  • Vertex Pharmaceuticals
  • Alexion Pharmaceuticals
  • BioMarin Pharmaceutical
  • Shire (now part of Takeda)
  • Sanofi Genzyme
  • Celgene (now part of Bristol Myers Squibb)
  • Genentech (a subsidiary of Roche)
  • Pfizer
  • Novartis
  • Johnson & Johnson
  • AbbVie
  • Amgen
  • Ultragenyx Pharmaceutical
  • CSL Behring
  • Merck & Co.
  • Grifols
  • Sobi (Swedish Orphan Biovitrum)
  • Ipsen
  • Jazz Pharmaceuticals
  • AstraZeneca
Customization scope

Free report customization with purchase. Customization includes:-

  • Segments by type, application, etc
  • Company profile
  • Market dynamics & outlook
  • Region

To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.

Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share

Table Of Content

Executive Summary

Market overview

  • Exhibit: Executive Summary – Chart on Market Overview
  • Exhibit: Executive Summary – Data Table on Market Overview
  • Exhibit: Executive Summary – Chart on Global Orphan Drug Market Characteristics
  • Exhibit: Executive Summary – Chart on Market by Geography
  • Exhibit: Executive Summary – Chart on Market Segmentation
  • Exhibit: Executive Summary – Chart on Incremental Growth
  • Exhibit: Executive Summary – Data Table on Incremental Growth
  • Exhibit: Executive Summary – Chart on Vendor Market Positioning

Parent Market Analysis

Market overview

Market size

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • SWOT Analysis

KEY MARKET INSIGHTS

  • Technology Analysis
    • (Exhibit: Data Table: Name of technology and details)
  • Pricing Analysis
    • (Exhibit: Data Table: Name of technology and pricing details)
  • Supply Chain Analysis
    • (Exhibit: Detailed Supply Chain Presentation)
  • Value Chain Analysis
    • (Exhibit: Detailed Value Chain Presentation)
  • Ecosystem Of the Market
    • Exhibit: Parent Market Ecosystem Market Analysis
    • Exhibit: Market Characteristics of Parent Market
  • IP Analysis
    • (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
  • Trade Analysis
    • (Exhibit: Data Table: Import and Export data details)
  • Startup Analysis
    • (Exhibit: Data Table: Emerging startups details)
  • Raw Material Analysis
    • (Exhibit: Data Table: Mapping of key raw materials)
  • Innovation Matrix
    • (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
  • Pipeline product Analysis
    • (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
  • Macroeconomic Indicators

COVID IMPACT

  • Introduction
  • Impact On Economy—scenario Assessment
    • Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
  • Revised Market Size
    • Exhibit: Data Table on Global Orphan Drug Market size and forecast 2021-2027 ($ million)
  • Impact Of COVID On Key Segments
    • Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
  • COVID Strategies By Company
    • Exhibit: Analysis on key strategies adopted by companies

MARKET DYNAMICS & OUTLOOK

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • Regulatory Landscape
    • Exhibit: Data Table on regulation from different region
  • SWOT Analysis
  • Porters Analysis
    • Competitive rivalry
      • Exhibit: Competitive rivalry Impact of key factors, 2021
    • Threat of substitute products
      • Exhibit: Threat of Substitute Products Impact of key factors, 2021
    • Bargaining power of buyers
      • Exhibit: buyers bargaining power Impact of key factors, 2021
    • Threat of new entrants
      • Exhibit: Threat of new entrants Impact of key factors, 2021
    • Bargaining power of suppliers
      • Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
  • Skyquest special insights on future disruptions
    • Political Impact
    • Economic impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Market Size by Region

  • Chart on Market share by geography 2021-2027 (%)
  • Data Table on Market share by geography 2021-2027(%)
  • North America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • USA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Canada
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Europe
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Germany
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Spain
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • France
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • UK
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Europe
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Asia Pacific
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • China
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • India
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Japan
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Korea
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Asia Pacific
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Latin America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Brazil
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of South America
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Middle East & Africa (MEA)
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • GCC Countries
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Africa
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of MEA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)

KEY COMPANY PROFILES

  • Competitive Landscape
    • Total number of companies covered
      • Exhibit: companies covered in the report, 2021
    • Top companies market positioning
      • Exhibit: company positioning matrix, 2021
    • Top companies market Share
      • Exhibit: Pie chart analysis on company market share, 2021(%)

Methodology

For the Global Orphan Drug Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:

1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.

2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Global Orphan Drug Market.

3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.

4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.

Analyst Support

Customization Options

With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Global Orphan Drug Market:

Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.

Regional Analysis: Further analysis of the Global Orphan Drug Market for additional countries.

Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.

Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.

Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.

Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.

Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.

Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.

$5,300
BUY NOW GET SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

SPEAK TO AN ANALYST

FAQ's

Orphan Drug Market size was valued at USD 87.44 billion in 2021 and is poised to grow from USD 174.11 billion in 2022 to USD 359.86 billion by 2030, growing at a CAGR of 9.5% in the forecast period (2023-2030).

The Global Orphan Drug Market is relatively fragmented, with a high level of competition. The prominent players operating in the orphan drug market are constantly 'Vertex Pharmaceuticals', 'Alexion Pharmaceuticals', 'BioMarin Pharmaceutical', 'Shire (now part of Takeda)', 'Sanofi Genzyme', 'Celgene (now part of Bristol Myers Squibb)', 'Genentech (a subsidiary of Roche)', 'Pfizer', 'Novartis', 'Johnson & Johnson', 'AbbVie', 'Amgen', 'Ultragenyx Pharmaceutical', 'CSL Behring', 'Merck & Co.', 'Grifols', 'Sobi (Swedish Orphan Biovitrum)', 'Ipsen', 'Jazz Pharmaceuticals', 'AstraZeneca'

The development of orphan medications under research has been significantly influenced by the development of new technologies.  Due recent advancements in genomics and the wider application of gene sequencing, made it possible in case of rare disease.  furthermore, additional technologies like gene therapy and antisense therapy have made it feasible for us to target certain disorders in ways that were not previously possible.  Combined, technological advancements have made it easier to both diagnose and cure uncommon genetic disorders, which has made them more manageable for pharmaceutical companies.

Since companies employ far lower criteria for showing treatment effectiveness, the expansion of the use of auxiliary or surrogate endpoints within clinical trials for orphan pharmaceuticals has significantly reduced the time and cost needed to undertake R&D. This can accelerate the growth of the Orphan Drug Market. 

In terms of CAGR, North America is expected to grow quickly in the years to come. This is attributed to the increase in patients in this area who are susceptible to rare diseases. The unhealthy lifestyle and stressful lifestyle are the key factors that cause this disease to spread in this area. In order to reduce the number of patients brought on by this disease, government organisations like NGO are investing a significant amount of money in this region.

Speak With Our Analyst

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Orphan Drug Market

Product ID: SQMIG30A2005

$5,300
BUY NOW GET SAMPLE